Merck & Co. MRK,
is in advanced discussions to acquire Seagen Inc. SGEN,
and is aiming to complete the purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth about $40 billion or more.
The companies are discussing a price for Seagen in excess of $200 per share and are attempting to seal a deal at or before Merck’s release of second fiscal quarter results, which are scheduled for July 28, the people said. Seagen shares closed at $175.13 on Wednesday.
https://www.marketwatch.com/story/merck-in-talks-to-buy-cancer-biotech-seagen-for-about-40-billion-11657161739?rss=1&siteid=rss Merck is in talks to buy cancer biotech Seagen for around $40 billion